Related Experiment Videos
Matrix metalloproteinase inhibitors: current developments and future perspectives
R Hoekstra1, F A Eskens, J Verweij
1Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek and University Hospital, Rotterdam, The Netherlands. hoekstra@oncd.azr.nl
Abstract:
Malignant tumors are characterized by invasive growth and metastasis. To facilitate this invasive behavior, the enzymatic breakdown of the extracellular matrix (ECM) is a prerequisite. Many human tumors are characterized by locally increased concentrations of matrix metalloproteinases (MMPs), enzymes that are able to degrade this ECM. A vast number of matrix metalloproteinase inhibitors (MMPIs) have been developed in recent years and after extensive preclinical testing, the results of the first clinical studies with several of these compounds have recently been presented. In this review we will describe some of the basic concepts of the degradation of the ECM, with special emphasis on the role of MMPs in the progression of cancer. Furthermore we will review the results of preclinical and clinical studies with MMPIs and discuss their future perspective.
Insights
Matrix metalloproteinases (MMPs) degrade the extracellular matrix, aiding tumor invasion and metastasis. Matrix metalloproteinase inhibitors (MMPIs) are being developed to target this process, with early clinical studies showing promise for cancer treatment.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Malignant tumors exhibit invasive growth and metastasis, processes facilitated by the enzymatic degradation of the extracellular matrix (ECM).
- Elevated concentrations of matrix metalloproteinases (MMPs), enzymes crucial for ECM breakdown, are frequently observed in human tumors.
- The role of MMPs in cancer progression is a significant area of research.
Purpose of the Study:
- To review the fundamental mechanisms of ECM degradation.
- To emphasize the specific role of MMPs in cancer progression.
- To present an overview of preclinical and clinical studies involving matrix metalloproteinase inhibitors (MMPIs) and discuss their future therapeutic potential.
Main Methods:
- Review of existing literature on ECM degradation and MMPs.
- Analysis of preclinical data from studies on MMPIs.
- Evaluation of early clinical trial results for MMPIs.
Main Results:
- MMPs are key enzymes involved in ECM degradation, promoting tumor invasion and metastasis.
- Numerous MMPIs have been developed, with several undergoing clinical evaluation.
- Initial clinical studies with MMPIs have yielded preliminary results that warrant further investigation.
Conclusions:
- Targeting MMPs with MMPIs represents a potential therapeutic strategy for cancer.
- Further research and clinical trials are necessary to establish the efficacy and safety of MMPIs.
- The future perspective for MMPIs in cancer treatment is cautiously optimistic, pending further data.